INVESTOR RELATIONS

News

Date Title and Summary Additional Formats
Toggle Summary NantKwest Appoints Dr. John Lee as Senior Vice President of Adult Medical Affairs
Company Adds Immuno-Oncology and Clinical Trial Expert to Leadership Team CULVER CITY, Calif. --(BUSINESS WIRE)--May 18, 2017-- NantKwest Inc.  (NASDAQ:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural
View HTML
Toggle Summary NantKwest Appoints Dr. Leonard Sender as Senior Vice President of Medical Affairs for Pediatric, Adolescent and Young Adult Oncology
Company adds esteemed pediatric, adolescent and young adult oncology expert to leadership team CULVER CITY, Calif. --(BUSINESS WIRE)--May 16, 2017-- NantKwest Inc . (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune
View HTML
Toggle Summary NantKwest Augments, Strengthens Senior Management Team
-- Company Adds Clinical Development , Medical Affairs and M&A Executives -- CULVER CITY, Calif. --(BUSINESS WIRE)--Sep. 22, 2015-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using natural killer cells to
View HTML
Toggle Summary NantKwest Builds Financial and Commercial Expertise with the Appointment of Fred Driscoll to Its Board of Directors
CULVER CITY, Calif. --(BUSINESS WIRE)--Sep. 22, 2017-- NantKwest, Inc. (Nasdaq:NK) today announced that Fred Driscoll , currently an Advisor and former Chief Financial Officer of Flexion Therapeutics, Inc. , has been appointed to the Board to fill the position being vacated by Mr.
View HTML
Toggle Summary NantKwest Chairman & CEO Dr. Patrick Soon-Shiong Exercises $39 Million in Warrants and Options in Support of NK’s Natural Killer Cell Strategic Vision Beyond Check Point Immunotherapy
Completion of Phase 1 First-in-Human Trials of Cryopreserved, Off-The-Shelf haNK Cells Leads the Way to Pivotal Phase 2 Trials in Relapsed Merkel Cell Carcinoma Funding to Support INDs for First-in-Human Targeted Off-The-Shelf NK Cells (t-haNKs) with PD-L1 and CD-19 as Tumor Targets CULVER CITY,
View HTML
Toggle Summary NantKwest Chairman & CEO Dr. Patrick Soon-Shiong to Present Vision for Next Generation Natural Killer Cell Therapies During Keynote Address at Innate Killer Summit
SAN DIEGO & CULVER CITY, Calif. --(BUSINESS WIRE)--Mar. 18, 2019-- NantKwest ( Nasdaq:NK ), a leading clinical-stage, natural killer cell based therapeutics company, today announced that the company’s Chairman & CEO, Dr. Patrick Soon-Shiong , will be giving a keynote address at the Innate Killer
View HTML
Toggle Summary NantKwest Continues the Strengthening of Its Leadership Team and Appoints a Seasoned Bioprocessing Manufacturing Executive
Stephen Farrand , Ph.D., former Merck executive appointed Senior Vice President Global Manufacturing CULVER CITY, Calif. --(BUSINESS WIRE)--Oct. 6, 2015-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using
View HTML
Toggle Summary NantKwest Doses First Patient in Phase 2 Single-Arm Trial of Metastatic Merkel Cell Carcinoma Therapy With Off-the-Shelf CD16 Natural Killer Cells
Clinical trial for patients failing checkpoint therapy uses combination of first-in-class, cryopreserved, CD16 NK cells, ImmunityBio’s IL-15 superagonist and checkpoint inhibitor Avelumab EL SEGUNDO, Calif. --(BUSINESS WIRE)-- NantKwest, Inc. (Nasdaq: NK), a next-generation, clinical-stage
View HTML
Toggle Summary NantKwest Hosting Key Opinion Leader Meeting on Novel Immunotherapeutic Approaches to Address the Unmet Medical Needs of Patients with Merkel Cell Carcinoma, Triple-Negative Breast Cancer and Solid Tumors
CULVER CITY, Calif. --(BUSINESS WIRE)--Nov. 27, 2019-- NantKwest, Inc. (Nasdaq: NK), a next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and other diseases, today
View HTML
Toggle Summary NantKwest Launches First-in-class, First-in-human Phase I Clinical Trial With a Targeted PD-L1 t-haNK Cell Therapy in Patients With Solid Tumors
First engineered, GMP-grade, cryopreserved, off-the-shelf, bi-specific NK cell therapy to enter human clinical trials targeting PD-L1 and CD16 in patients with solid tumors NantKwest establishes a leading portfolio of off-the-shelf NK cells at clinical stage of development with three engineered
View HTML